Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Incidence and risk factors for infections in the real-world setting in newly diagnosed myeloma patients treated with modern induction regimens

View Full Paper
Ask AI
Bookmark
Share

Authors

EKEfstathios KastritisESEirini SoliaINIoannis Ntanasis‐Stathopoulos

Discussion

Loading...

Member takes

Overview

Observational analysis recorded infections in newly diagnosed myeloma patients, indicating high mortality risks from poor performance status and serum albumin levels.

Key Points

  • At least one infection was recorded in 31% of newly diagnosed myeloma patients treated with modern regimens.
  • Cumulative infection rates were 14%, 20%, and 29% at 3, 6, and 12 months, highlighting early high risk.
  • Analysis included 541 patients starting treatment after 2020, emphasizing the role of multifactorial risk factors.
  • More effective modern induction regimens did not increase risk, indicating the need for preventive strategies.

Cite This Study

Kastritis et al. (2025) studied this question.

synapsesocial.com/papers/69362f4b4fa91c937236d7dbhttps://doi.org/10.1182/blood-2025-2228
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Immune biomarkers of increased risk of infection in multiple myeloma (MM)2025
  2. 2Infection rates and mortality in multiple myeloma: Impact of blood counts and IgG levels over time2025
  3. 3Incidence of severe infections in patients with multiple myeloma treated with immunoglobulin-replacement therapy2025
  4. 4Infection events in patients with newly diagnosed multiple myeloma with anti-CD38 monoclonal antibody-based first line regimens: A multicentric Italian experience2025
  5. 5Infection risk factors and burden in patients treated with T-cell engaging bispecific antibodies for relapsed B-cell lymphoma and multiple myeloma2025